CD8A and neoplasm: Compared to IgG treatment, cusatuzumab treatment inhibited the suppressive activity of Tregs, which in turn activated the effector function of CD8+ T cells, eventually resulting in an enhanced tumor-killing efficacy (Supplementary Figs. 4m–p).